Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Matthias Pauschinger, F. Stephen Hodi, Patrick A. Ott, Thomas F. Gajewski, Hussein Tawbi, Jason J. Luke, Lucie Heinzerling, Aliya N. Husain, Azadeh Tajmir-Riahi, Evan J. Lipson
التنسيق: مقال
اللغة:English
منشور في: BMJ Publishing Group 2016-06-01
سلاسل:Journal for ImmunoTherapy of Cancer
الوصول للمادة أونلاين:https://jitc.bmj.com/content/4/1/50.full

مواد مشابهة

مواد مشابهة